Abstract
Vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) in primary malignant gastric lymphoma were studied, and their correlation as well as its clinical significance was analyzed. Thirty-five patients diagnosed with primary malignant gastric lymphoma were enrolled in this study. VEGF expression in the tumor tissues was detected by immunohistochemistry. Microvessel density in tumors was counted with Weidner’s method and compared with MVD in normal tissues 5 cm away from tumor site. Collected data were analyzed statistically. Our results showed that VEGF expression and MVD in tumor tissues were higher than those in normal tissues, and the difference between these two groups was significant (P < 0.01). As VEGF expression was elevated, MVD was also increased in tumor tissues. Statistical analysis revealed that VEGF expression was positively correlated with MVD (r = 0.392, P < 0.05). VEGF was highly expressed in primary malignant gastric lymphoma and positively correlated with MVD. These results strongly suggest that anti-angiogenesis therapy investigated in gastric lymphoma is a prospective clinical trial.
Similar content being viewed by others
References
Ferrarar N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4–25.
Carron CP, Meyer DM, Pegg JA, Engleman VW, Nickols MA, Settle SL. A peptidomimetic antagonist of the integrin alpha (v) beta 3 inhibits leydig cell tumor growth and development of hypercalcemia of malignancy. Cancer Res. 1998;58:1930–5.
Folkman J, D’Amore PA. Blood vessel formation: what is its molecular basis? Cell. 1996;87:1153–5.
Weidner N, Semple JP, Welch W, Folkman J. Tumor angiogenesis and metastasis. Correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8.
Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart M. Quantitative angiogenesis assessed by anti-PECAM antibodies: correlation with node metastasis and survival in breast cancer. Lancet. 1992;340:1120–4.
Vartanian RK, Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol. 1994;144:1188–94.
Wakui S, Furusato M, Sasaki H, Akiyama A, Kinoshito I, Asano K. Tumor angiogenesis in prostatic carcinoma with and without bone metastasis: a morphometric study. J Pathol. 1992;168:257–62.
Macchiarini P, FontaniniGHardin MJ, Squartini F, Angeletti CA. Relation of neovascularization to metastasis of non-small cell lung carcinoma. Lancet. 1992;340:145–6.
Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol. 1993;24:220–6.
Smith-McCune KS, Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res. 1994;54:804–8.
Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29:252–60.
Herrmann R, Panahon AM, Barcos MP, Walsh D, Stutzman L. Gastrointestinal involvement in non-Hodgkin’s lymphoma. Cancer. 1980;46:215–22.
Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Haematol. 2007;136:521–38.
Cogliatti SB, Schmid U, Schumacher U, Eckert F, Hansmann ML, Hedderich J. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology. 1991;101:1159–70.
Buchler P, Reber HA, Buchler MW, Friess H, Hines OJ. VEGF influences the prognosis of panc reatic cancer. Ann Surg. 2002;236:728–49.
Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8.
Ding G, Huang S, Chen XJ, Liu DH. The Relationship between VEGF in Experimental Rat and Tumor Angiogenesis Invasion and Metastasis. Pract J Cancer. 2010;25:551–3.
Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401–10.
Yu MJ, Li HM. Advances in angiogenesis inhibitors of lymphoma. Journal of Pract Oncol. 2005;19:69–72.
Tang QL, Jiang XF, Yang KZ, Li HG, Liu WP, Peng ZL. Expression of VEGF and its significance in primary diffuse large B-cell lymphoma of the female genital system. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009;40:48–51.
Ni Q, Wu ZS, Wu Q, Zhang SM, Zhou Q, Wang Y. Expression of ESM-1 and VEGF in non-Hodgkin lymphoma. Anhui Med Pharm J. 2004;9:104–5.
Filipits M, Jaeger U, Simonitsch I, Chizzali-Bonfadin C, Heinzl H, Pirker R. Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas. Clin Cancer Res. 2000;6:3417–23.
Zeng CQ, Zheng Y, Huang LX, Li JD. Analysis of prognostic factors in lymph node-negative advanced gastric cancer patients. Zhonghua Wei Chang Wai Ke Za Zhi. 2011;14:111–3.
Verheul HM, Hoekmank K, Joma AS, Smit EF, Pinedo HM. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist. 2000;5:45–50.
Ho CL, Sheu LF, Li CY. Immunohistochemical Expression of Basic Fibroblast Growth Factor, Vascular Endothelial Growth Factor, and Their Receptors in Stage IV Non-Hodgkin Lymphoma. Appl Immunohistochem Mol Morphol. 2002;10:316–21.
Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J. Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma. 2006;47:998–1005.
Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol. 2011;17:697–707.
Acknowledgments
Supported by Yunnan provincial department of education research funds (5Y04320).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xie, L., Shen, LD., Qing, C. et al. Correlational study of vascular endothelial growth factor expression and microvessel density in primary malignant gastric lymphoma. Med Oncol 29, 1711–1715 (2012). https://doi.org/10.1007/s12032-011-0008-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-011-0008-8